Clinical Trials Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Oct 26, 2021; 9(30): 9059-9069
Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9059
Table 1 Baseline characteristics
Dexamethasome (n = 49)
Placebo (n = 51)
P value

n
%
n
%
Sex0.721
Male4081.604384.30
Female918.40815.70
Age (yr)0.679
mean ± SD61.18 ± 11.1361.82 ± 10.68
Size (cm)0.154
Median (min-max)3.9(0.40-18.30)5.4(0.80-18.00)0.061
> 3 cm3061.204078.40
Etiology 0.209
Hepatitis B2244.902243.10
Hepatitis C1734.701427.50
Cryptogenic36.101121.60
Alcoholic cirrhosis510.2035.90
NASH12.0000
BCLC staging0.154
A1122.40713.70
B3673.504486.30
ECOG performance status0.845
0714.301019.60
13979.603976.50
Child-Pugh class0.511
A4183.704588.20
B816.30611.80
AFP level0.72
None4693.905098.00
> 400 ng/mL1020.40917.60
No of TACE0.744
12959.203160.80
2918.40917.60
Embolization agent0.619
Lipiodol plus doxorubicin1530.601835.30
Lipiodol plus mitomycin-C3469.403364.70
Lipiodol dose0.483
mean ± SD10.67 ± 3.0110.14 ± 1.60
Level of embolisation0.612
Right branch3061.203670.60
Left branch1122.40815.70
Main trunk714.30713.70
Diabetes mellitus0.806
None3061.203058.80
Diabetes mellitus1938.802141.20
Table 2 Univariate and multivariate analysis of factors associated with the development of postembolization syndrome
FactorsUnivariate analysis
Multivariate analysis
OR
95%CI
P value
OR
95%CI
P value
Size > 3 cm4.21.672-10.5530.002a3.6611.395-9.6050.008a
Dexamethasone0.2420.105-0.5590.001a0.2710.114-0.6470.003a